Opportunity Information: Apply for RFA AI 14 012
Apply for RFA AI 14 012
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "HLA and KIR Region Genomics in Immune Mediated Diseases (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 9, 2014 and posted on Jun 9, 2014.
- Applicants must submit their applications by Oct 20, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,400,000.00 to eligible and selected applicants.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Private institutions of higher education Small businesses Independent school districts For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) State governments County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign Institutions Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The HLA and KIR Region Genomics in Immune Mediated Diseases (U01) funding opportunity (RFA-AI-14-012) was a National Institutes of Health (NIH) cooperative agreement designed to build and expand a multi-institution research consortium focused on two highly complex and medically important parts of the human genome: the human leukocyte antigen (HLA) region, also known as the major histocompatibility complex (MHC), and the killer cell immunoglobulin-like receptor (KIR) region. The program supported research that clarifies how inherited variation across these regions influences immune-mediated diseases and clinically important immune outcomes, explicitly including outcomes after cell, tissue, and solid organ transplantation. In practical terms, the goal was to move beyond broad genetic associations and produce more precise, functionally meaningful understanding of which HLA and KIR variants (and variant combinations) drive risk, protection, and differential outcomes across immune-related conditions.
The mechanism was a U01 cooperative agreement, which typically means NIH staff are expected to have substantial scientific involvement during the project period compared with a standard research grant. This structure fits a consortium model where groups coordinate on shared standards, data generation approaches, analytical strategies, and cross-project integration. The opportunity was tied to the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLAGC), described as the continuation and expansion of an earlier effort (formerly the HLA Region Genomics in Immune Mediated Diseases Consortium). The emphasis on both HLA and KIR reflects the biology: HLA molecules are central to antigen presentation and T cell responses, while KIR genes regulate natural killer (NK) cell activity and interact with specific HLA class I ligands. Because these loci are extraordinarily polymorphic, structurally complex, and often poorly captured by conventional genotyping arrays, focused genomic efforts are needed to characterize them accurately and relate them to disease phenotypes and transplant outcomes.
From a funding and administrative standpoint, the FOA was categorized as discretionary funding and fell under the NIH health research activity categories, with CFDA listings that included allergy and infectious diseases research, microbiology and infectious diseases research, and extramural research programs in neurosciences and neurological disorders. The estimated total funding level for the announcement was about $3.4 million, with no cost sharing or matching requirement. Key dates show it was posted on June 9, 2014, with an original and current closing date of October 20, 2014, and it was archived on November 20, 2014. While the archived status means it is no longer open, the details still matter as a reference point for how NIH structured consortium-based genomics efforts around immunogenetic regions.
Eligibility was broad and included many types of domestic U.S. organizations and governments, such as public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses, for-profit organizations (including those other than small businesses), and multiple levels of government (state, county, city/township, special district), as well as independent school districts and public housing authorities/Indian housing authorities. The FOA also explicitly included categories often highlighted by NIH for inclusive participation, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions (AANAPISIs), along with faith-based/community-based organizations, regional organizations, and eligible federal agencies. Foreign institutions and other non-U.S. entities were not eligible to apply directly, and non-U.S. components of U.S. organizations were also not eligible. However, the FOA allowed foreign components as defined by the NIH Grants Policy Statement, meaning U.S. applicants could potentially include certain foreign collaborations when justified and compliant with NIH policy.
Overall, this opportunity was aimed at assembling a coordinated set of projects capable of delivering high-resolution genomics and rigorous association analyses in the HLA/MHC and KIR regions, areas that are central to immune recognition, autoimmunity, infectious disease response, and transplant compatibility and outcomes. The consortium framing and cooperative agreement mechanism signaled that applicants were expected not only to pursue strong individual research aims, but also to contribute to shared resources, harmonized methods, and collaborative analyses that accelerate progress across the broader immunogenomics community. For full official details, the FOA pointed to the NIH guide notice at http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-012.html and provided NIH Office of Extramural Research (OER) webmaster contacts for access and linking issues.
FAQs: HLA and KIR Region Genomics in Immune Mediated Diseases (U01) - RFA-AI-14-012
What is this funding opportunity?
This opportunity, titled "HLA and KIR Region Genomics in Immune Mediated Diseases (U01)" (RFA-AI-14-012), was a National Institutes of Health (NIH) cooperative agreement designed to build and expand a multi-institution research consortium focused on the HLA (also called the MHC) and KIR genomic regions.
What was the main purpose of the program?
The program supported research to clarify how inherited genetic variation in the HLA/MHC and KIR regions influences immune-mediated diseases and clinically important immune outcomes, explicitly including outcomes after cell, tissue, and solid organ transplantation. A central goal was to move beyond broad genetic associations toward more precise, functionally meaningful identification of specific variants and variant combinations that drive risk, protection, and differential outcomes.
What genomic regions were targeted, and why are they important?
The focus was on two complex and medically important parts of the human genome:
- HLA region (MHC): Central to antigen presentation and T cell responses.
- KIR region: Regulates natural killer (NK) cell activity and interacts with specific HLA class I ligands.
These loci are highly polymorphic and structurally complex, and they are often not well captured by conventional genotyping arrays, which is why dedicated genomic approaches are needed.
What kinds of outcomes and conditions were included?
The FOA emphasized immune-mediated diseases and clinically important immune outcomes. It explicitly included immune outcomes following cell transplantation, tissue transplantation, and solid organ transplantation.
What is the funding mechanism?
The mechanism was a U01 cooperative agreement. This typically indicates that NIH staff are expected to have substantial scientific involvement during the project period compared with a standard research grant.
Why was a cooperative agreement (U01) used instead of a standard grant?
The U01 structure fit a consortium model where multiple groups coordinate on shared standards, data generation approaches, analytical strategies, and cross-project integration. The cooperative agreement format supports close coordination between funded teams and NIH staff.
What consortium was associated with this FOA?
The opportunity was tied to the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLAGC), described as the continuation and expansion of an earlier effort (formerly the HLA Region Genomics in Immune Mediated Diseases Consortium).
What types of research activities were expected?
Based on the description, projects were expected to deliver high-resolution genomics and rigorous association analyses in the HLA/MHC and KIR regions. Applicants were also expected to contribute to shared resources, harmonized methods, and collaborative analyses to accelerate progress across the broader immunogenomics community.
How much funding was available?
The estimated total funding level for the announcement was about $3.4 million.
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement.
How was this FOA categorized from an administrative standpoint?
The FOA was categorized as discretionary funding and fell under NIH health research activity categories. CFDA listings mentioned included allergy and infectious diseases research, microbiology and infectious diseases research, and extramural research programs in neurosciences and neurological disorders.
When was the opportunity posted and when did it close?
- Posted: June 9, 2014
- Closing date (original and current): October 20, 2014
Is the opportunity still open?
No. The FOA is archived. It was archived on November 20, 2014, and is no longer open for applications.
Why might this archived FOA still be useful?
Even though it is no longer open, the FOA can still serve as a reference point for how NIH structured consortium-based genomics efforts around complex immunogenetic regions (HLA/MHC and KIR), including expectations for collaboration, harmonized methods, and integrated analyses.
Who was eligible to apply?
Eligibility was broad and included many types of domestic U.S. organizations and governments, including:
- Public and private institutions of higher education
- Nonprofits with and without 501(c)(3) status
- Small businesses
- For-profit organizations (including those other than small businesses)
- State, county, city/township, special district governments
- Independent school districts
- Public housing authorities/Indian housing authorities
- Eligible federal agencies
- Regional organizations
- Faith-based/community-based organizations
Were minority-serving institutions explicitly included as eligible applicants?
Yes. The FOA explicitly included categories often highlighted by NIH for inclusive participation, including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and AANAPISIs.
Could foreign institutions apply directly?
No. Foreign institutions and other non-U.S. entities were not eligible to apply directly.
Were non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations were not eligible.
Were foreign collaborations allowed at all?
Yes, in a limited way. The FOA allowed foreign components as defined by the NIH Grants Policy Statement, meaning U.S. applicants could potentially include certain foreign collaborations when justified and compliant with NIH policy.
What makes HLA and KIR genomics challenging enough to warrant a dedicated consortium effort?
The HLA/MHC and KIR loci are extraordinarily polymorphic and structurally complex. Conventional genotyping arrays often do not capture them well, so specialized, focused genomic efforts are needed to characterize them accurately and relate variation to disease phenotypes and transplant outcomes.
Where could applicants find the official FOA details?
The FOA directed readers to the NIH guide notice at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-012.html
Who was listed for help with access and linking issues?
The FOA referenced NIH Office of Extramural Research (OER) webmaster contacts for access and linking issues.
Browse more opportunities from the same category: Health
Next opportunity: HLA and KIR Region Genomics in Immune Mediated Diseases (U19)
Previous opportunity: Sun Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| HLA and KIR Region Genomics in Immune Mediated Diseases (U19) Apply for RFA AI 14 013 Funding Number: RFA AI 14 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement to Support Navigators in Federally facilitated and State Partnership Marketplaces Apply for CA NAV 14 002 Funding Number: CA NAV 14 002 Agency: CMS Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| Advancing National Public Health Institutes Globally Apply for CDC RFA GH14 1419 Funding Number: CDC RFA GH14 1419 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIOSH Support for Conferences and Scientific Meetings (R13) Apply for PAR 14 246 Funding Number: PAR 14 246 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $20,000 |
| Research Supplements for Aging Research on Health Disparities (Admin Supp) Apply for PA 14 256 Funding Number: PA 14 256 Agency: National Institutes of Health Category: Health Funding Amount: $62,500 |
| Training Seminars on Safe Medicine Apply for NDRFP14 05 Funding Number: NDRFP14 05 Agency: U.S. Mission to India Category: Health Funding Amount: $14,000 |
| Mentored Career Development Award to Build Research Capacity in Global Mental Health (K01) Apply for RFA MH 15 700 Funding Number: RFA MH 15 700 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01) Apply for RFA MH 15 600 Funding Number: RFA MH 15 600 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Severe Combined Immunodeficiency (SCID) Newborn Screening Implementation Program Apply for HRSA 14 139 Funding Number: HRSA 14 139 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,000,000 |
| Leadership in Public Health Social Work Education Apply for HRSA 14 145 Funding Number: HRSA 14 145 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries Apply for CDC RFA PS14 1411 Funding Number: CDC RFA PS14 1411 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Health Careers Opportunity Program Skills Training and Health Workforce Development of Paraprofessionals Apply for HRSA 14 144 Funding Number: HRSA 14 144 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Tribal Public Health Capacity Building and Quality Improvement Cooperative Agreement Apply for CDC RFA OT13 130302CONT14 Funding Number: CDC RFA OT13 130302CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Parkinsons Disease Biomarker Program (PDBP) Discovery Projects (U01) Apply for PAR 14 259 Funding Number: PAR 14 259 Agency: National Institutes of Health Category: Health Funding Amount: $490,000 |
| Centers for Medical Countermeasures against Radiation Consortium (U19) Apply for RFA AI 14 055 Funding Number: RFA AI 14 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PPHF 2014 Racial and Ethnic Approaches to Community Health (REACH) financed in part by Prevention and Public Health Funding Apply for CDC RFA DP14 1419PPHF14 Funding Number: CDC RFA DP14 1419PPHF14 Agency: NCCDPHP Category: Health Funding Amount: $500,000 |
| PPHF 2014 Immunization Capacity Building Assistance for Infrastructure Enhancements to Meet Interoperability Requirements financed in part by 2014 Prevention and Public Health Funds Apply for CDC RFA IP14 1404PPHF14 Funding Number: CDC RFA IP14 1404PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Methods Development in Natural Products Chemistry (R43/R44) Apply for RFA AT 15 003 Funding Number: RFA AT 15 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Methods Development in Natural Products Chemistry (STTR) (R41) Apply for RFA AT 15 002 Funding Number: RFA AT 15 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| American Indians into Psychology Apply for HHS 2014 IHS INPSY 0001 Funding Number: HHS 2014 IHS INPSY 0001 Agency: Indian Health Service Category: Health Funding Amount: $238,359 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.